Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). The pathophysiology of BO is, however, poorly known. The available data strongly support the role of respiratory viruses, in particular paramyxoviruses (parainfluenzae virus (PIV), respiratory syncytial virus, metapneumovirus). It is likely that the alloimmune response triggered by the respiratory virus is inadequate and leads to the peribronchiolar fibrotic process. The objective is to analyze the kinetics of profiles of the blood and respiratory host responses resulting from a high or low parainfluenza respiratory infection, in order to evaluate if the occurrence of a BO is associated with a specific signature We will evaluate the predictive signature of a BO after a parainfluenza virus infection by characterizing the differences between the patients evolving and those not evolving to a BO at 2 months after the infection.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults having received a hematopoietic stem cell transplantation for less than two years

Availability of respiratory function tests prior to infection

Presence of PIV respiratory infection documented by identification of the virus by PCR in the upper and/or lower respiratory tract

Symptoms of respiratory infection ≤ 5 days

Disqualifiers

Presence of a respiratory virus infection other than PIV

Viral respiratory co-infections

Bacterial or fungal respiratory infections

Treatment with ribavirin, oseltamivir or any other antiviral with activity against respiratory viruses

Trial population

Adult recipients of allogeneic HSCT with PIV pulmonary infection

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

  • samples

    Other intervention

    blood sample nasal swab

Treatment groups

14 Participants
are divided into 2 treatment groups
Group A: Cases1 intervention
Group B: Controls1 intervention

Trial outcomes

Primary outcomes

1

Host response in both blood and respiratory tract after PIV infection

Time frame
Up to 6 months

Secondary outcomes

1

Identify the cellular signaling pathways associated with the development of BO following parainfluenzae virus infection

Time frame
Up to 6 months
2

Evaluate differences in transcriptomic profiles between blood and respiratory tract

Time frame
Up to 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.